ClinicalTrials.Veeva

Menu
B

Bhakti Vedanta Hospital and Research Institute | Thane, India

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

LY573144
Lasmiditan
Pembrolizumab
PF-07220060
ARV-471
PF-07850327
Orforglipron
Lorlatinib
Tirzepatide
LY3298176

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 9 total trials

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2)

The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of m...

Enrolling
Migraine
Drug: Lasmiditan

Study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior...

Enrolling
Overweight or Obesity
OSA
Drug: Placebo
Drug: Orforglipron
Locations recently updated

The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the...

Active, not recruiting
Neoplasms
Drug: Cetuximab
Drug: Oxaliplatin

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks an...

Enrolling
Migraine
Drug: Placebo
Drug: Lasmiditan

The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).

Enrolling
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Drug: ABP 234
Drug: Pembrolizumab (EU)

The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diab...

Active, not recruiting
Type2 Diabetes
Glucose Metabolism Disorders
Drug: Placebo
Drug: Tirzepatide Dose 2

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Active, not recruiting
Advanced Breast Cancer
Drug: ARV-471
Drug: Fulvestrant

The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study d...

Enrolling
Advanced or Metastatic Breast Cancer
Drug: Everolimus
Drug: Fulvestrant

Trial sponsors

Lilly logo
Pfizer logo
Amgen logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems